title: Ertumaxomab: a trifunctional antibody for breast cancer treatment.
abstract: Ertumaxomab is an intact bispecific antibody targeting HER2/neu and CD3 with preferential binding to activating Fcgamma type I/III-receptors, resulting in the formation of a tri-cell complex among tumour cell, T cell and accessory cell. Recently, the antibody demonstrated antitumour efficacy against HER2/neu low-expressing tumours resistant to trastuzumab. Data from a completed Phase I study in metastatic breast cancer patients indicates strong immune responses. Owing to efficient tumour cell destruction by humoral and T-cell-dependent mechanisms, differing from conventional HER2/neu directed treatments, and a potential for long-lasting antitumour immunoreactivity, ertumaxomab is at present investigated within Phase II studies enrolling metastatic breast cancer patients even without HER2/neu gene amplification.
authors.affiliation: Charité Campus Benjamin Franklin, Department of Hematology and Oncology, Hindenburgdamm 30/31, D-12200 Berlin, Germany. philipp.kiewe@charite.de
authors.forename: Philipp
authors.initials: P
authors.lastname: Kiewe
authors.forename: Eckhard
authors.initials: E
authors.lastname: Thiel
mesh_terms: D018033:Antibodies, Bispecific / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D017252:CD3 Complex / Q000276:immunology; D017321:Clinical Trials, Phase I as Topic; D004353:Drug Evaluation, Preclinical; D005260:Female; D006801:Humans; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology
chemical_list: D018033:Antibodies, Bispecific; D000911:Antibodies, Monoclonal; D017252:CD3 Complex; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human; C511895:ertumaxomab